JPRN-UMIN000023046已完成未知
Study of Efficacy of Sirolimus in Patients with Activated PI3Kdelta Syndrome - Treatment of APDS with Sirolimus
Department of Human Genetics National Center for Child Health and Development0 个研究点目标入组 5 人开始时间: 2016年7月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with severe infections 2) Patients with severe thrombocytopenia
研究者
相似试验
已完成
不适用
Clinical study on efficacy and safety of sirolimus against epileptic seizures of focal cortical dysplasia type IIPatients with epilepsy with focal cortical dysplasia type 2JPRN-UMIN000030962Hokkaido University Hospital2
进行中（未招募）
1 期
A Phase I/II Study of Sirolimus (Rapamune TM) in Combination with Cyclophosphamide and Dexamethasone in Relapsed Myeloma - SCD1 TrialPlasma Cell MyelomaEUCTR2005-000656-33-GBRoyal Devon and Exeter NHS Foundation Trust18
进行中（未招募）
1 期
Prospective comparison of sirolimus against corticosteroids in treatment of patients with active thyroid eye diseaseThyroid eye diseaseCTIS2023-510166-27-01Helse Bergen HF70
进行中（未招募）
1 期
Sirolimus treatment in patients with autosomal dominant polycystic kidney disease renal efficacy and safety - NDEUCTR2006-003427-37-ITIST. DI RICERCHE FARMACOLOG. M. NEGRI16
进行中（未招募）
1 期
Effects of Sirolimus on disease progression in patients with Autosomal Dominant Polycystic Kidney Disease and severe renal insufficiency - SIRENA IIAutosomal Dominant Polycystic Kidney Disease (ADPKD)MedDRA version: 9.1 Level: LLT Classification code 10010428 Term: Congenital cystic kidney diseaseEUCTR2007-005047-21-ITIST. DI RICERCHE FARMACOLOG. M. NEGRI40